Products in the News

GSK Implements Genedata Biologics as Antibody Discovery Platform

Share Like Tweet Add Email

Genedata AG

Maulbeerstrasse 46, Basel, CH-4016, Switzerland

Original Press Release

GSK Implements Genedata Biologics as Antibody Discovery Platform

Press release date: May 28, 2014

Genedata Biologics integrates GlaxoSmithKline's Biopharm Discovery workflows across multiple Biopharm RD groups and sites

Basel, Switzerland¬†– Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Biopharm RD at GlaxoSmithKline (GSK) has selected Genedata Biologics™ as a key R&D data management and workflow-support platform. The Genedata Biologics platform will support multiple GSK Biopharm R&D groups including lead identification and screening, protein optimization and engineering, and protein production.

The system records, manages, and processes data from GSK's diverse antibody discovery platforms such as phage and yeast display, hybridoma, and other technologies, including proprietary ones. In addition, Genedata Biologics helps to improve data quality, improve efficiency through upload and export of instrument data, increase experimental throughput, and streamline workflows.

Genedata supports the deployment and roll-out of the Genedata Biologics system, its integration into GSK's R&D environment, and its use of Biopharm's high-throughput automation platforms. Genedata and GSK will work together to support new discovery technologies and next-generation antibody formats such as GSK's domain antibodies and other proprietary molecules and technologies.

As an integrated and scalable IT platform, Genedata Biologics makes it easy to share results across many groups involved in R&D projects. The system's built-in business logic supports the full diversity of GSK's complex and evolving antibody discovery processes.

"We are honored to have GSK, a global leader in biopharmaceuticals, chose Genedata Biologics as the platform to support their biopharmaceutical R&D processes," said Dr. Othmar Pfannes, CEO of Genedata. "The collaboration with GSK is another milestone on our path to establish Genedata Biologics worldwide as the platform of choice to streamline the discovery and development of novel biopharmaceuticals. We will continue to expand the platform to meet the quickly emerging new requirements in support of this highly innovative and important field."

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. www.genedata.com

Contacts
Allison Kurz
Genedata
Public Relations
Phone: +41 61 511 8459
pr@genedata.com

Genedata AG - Margarethenstrasse 38, 4053 Basel, Switzerland - Tel. +41 61 511 8400 - Fax +41 61 511 8484

Genedata Inc. - 750 Marrett Road, One Cranberry Hill, Suite 403, Lexington, MA 02421 - Tel. +1 781 357 4755 - Fax +1 781 357 4770

Genedata Inc. - 109 Stevenson Street, 4th Floor, San Francisco, CA 94105 - Tel. +1 877 436 3872 - Fax +1 415 970 6631

Genedata GmbH - Fürstenrieder Strasse 281, 81377 Munich, Germany - Tel. +49 89 4581 9010 - Fax +49 89 4581 9015

Genedata KK - 1-7-11-408, Higashi-Gotanda, Shinagawa-Ku, Tokyo 141-0022, Japan - Tel. +81 3 6721 7261 - Fax +81 3 6721 7262
www.genedata.com
pr@genedata.com  

Share Like Tweet Add Email

Comments

comments powered by Disqus